Nippon Chemiphar Co., Ltd. (JP:4539)

:4539

4539

Nippon Chemiphar Co., Ltd.

RESEARCH TOOLSreports

Nippon Chemiphar Co., Ltd. (4539) Price & Analysis

1 Followers

4539 Stock Chart & Stats

¥1585.00

-¥7.00(-0.46%)

At close: Jan 08 4:00 PM EST

¥1585.00

-¥7.00(-0.46%)

Day’s Range― - ―

52-Week Range¥1,422.00 - ¥1,857.00

Previous CloseN/A

Volume500.00

Average Volume (3M)2.30K

Market Cap

¥6.20B

Enterprise Value¥16.85B

Total Cash (Recent Filing)¥9.69B

Total Debt (Recent Filing)¥19.02B

Price to Earnings (P/E)11.6

Beta0.27

Next Earnings

May 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.21%

Share Statistics

EPS (TTM)34.21

Shares Outstanding4,261,420

10 Day Avg. Volume1,680

30 Day Avg. Volume2,300

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)0.28

Price to Sales (P/S)0.16

P/FCF Ratio-2.87

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balanced LeverageA debt-to-equity ratio near 0.94 with an equity ratio around 38.5% indicates a measured leverage profile and solid capital base. Over the next several months this reduces refinancing and solvency risk, preserves flexibility for R&D or manufacturing capex, and supports strategic responses to industry headwinds.

Margin Recovery And Improving ProfitabilityMoving from a loss to a positive net margin and rising EBITDA margin signals operational recovery and tighter cost control. This sustained improvement strengthens cash generation potential and capacity to fund pipeline activities or dividends, making future earnings less reliant on one-off items.

Durable Prescription Drug Revenue BaseA business focused on prescription pharmaceuticals sold into hospitals, clinics and wholesalers in Japan benefits from predictable, regulated demand and healthcare structural drivers. That durable revenue profile supports steady order flows, commercial scale and a platform for licensing or contract-manufacturing growth.

Bears Say

Negative Free Cash FlowPersistent negative operating and free cash flow constrains the company's ability to internally fund R&D, production capacity, and working capital. Over a multi-month horizon this elevates refinancing risk or forces trade-offs (cutting capex, delaying launches), weakening strategic optionality.

Inconsistent Revenue GrowthFluctuating top-line performance undermines predictability in a sector with lengthy development and commercialization timelines. Inconsistent revenue complicates budgeting for clinical or commercial investments and increases execution risk for lifecycle planning and returns on new product launches.

Low Capital EfficiencyA ROE near 1.5% combined with low net and EBIT margins indicates weak conversion of capital into profit. Over the medium term this suggests limited capacity to generate attractive shareholder returns, reducing reinvestment headroom and making the firm more vulnerable to competitive pricing or rising cost pressures.

4539 FAQ

What was Nippon Chemiphar Co., Ltd.’s price range in the past 12 months?

Nippon Chemiphar Co., Ltd. lowest stock price was ¥1422.00 and its highest was ¥1857.00 in the past 12 months.

What is Nippon Chemiphar Co., Ltd.’s market cap?

Nippon Chemiphar Co., Ltd.’s market cap is ¥6.20B.

When is Nippon Chemiphar Co., Ltd.’s upcoming earnings report date?

Nippon Chemiphar Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 34 days.

How were Nippon Chemiphar Co., Ltd.’s earnings last quarter?

Nippon Chemiphar Co., Ltd. released its earnings results on Jan 30, 2026. The company reported ¥34.21 earnings per share for the quarter, beating the consensus estimate of N/A by ¥34.21.

Is Nippon Chemiphar Co., Ltd. overvalued?

According to Wall Street analysts Nippon Chemiphar Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nippon Chemiphar Co., Ltd. pay dividends?

Nippon Chemiphar Co., Ltd. pays a Annually dividend of ¥50 which represents an annual dividend yield of 3.21%. See more information on Nippon Chemiphar Co., Ltd. dividends here

What is Nippon Chemiphar Co., Ltd.’s EPS estimate?

Nippon Chemiphar Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nippon Chemiphar Co., Ltd. have?

Nippon Chemiphar Co., Ltd. has 4,261,420 shares outstanding.

What happened to Nippon Chemiphar Co., Ltd.’s price movement after its last earnings report?

Nippon Chemiphar Co., Ltd. reported an EPS of ¥34.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Nippon Chemiphar Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4539

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.